Type II diabetes in adults, if the blood sugar level can not be maintained only by diet, exercise and weight loss.
active substance: glimepiride;
1 tablet contains glimepiride 4 mg;
excipients (4 mg tablets): lactose, sodium starch (type A), povidone K-30, microcrystalline cellulose, magnesium stearate, iron oxide red (E172), iron oxide yellow (E 172).
Glimax Dosage form
Basic physical and chemical properties: 4 mg tablets: light pink round flat tablets with a break line on one side and smooth on the other.
Glimax Pharmacotherapeutic group
Hypoglycemic agents, with the exception of insulins. Sulfonamides, urea derivatives. ATX code А10В 12.
Glimepiride is an orally active hypoglycemic substance that belongs to the sulfonylurea group. It can be used for type II diabetes mellitus.
Glimepiride works primarily by stimulating the release of insulin from the beta cells of the pancreas.
As with other sulfonylureas, this effect is based on an increase in the sensitivity of pancreatic cells to physiological glucose stimulation. In addition, glimepiride has a pronounced popancreatic effect, which is also typical for other sulfonylureas.
Release of insulin. Sulfonylurea drugs regulate insulin secretion by closing the ATP-dependent potassium channel located in the beta cell membrane of the pancreas. The closure of the potassium channel causes the beta cell to depolarize and, by opening the calcium channels, leads to an increase in the influx of calcium into the cell, which, in turn, leads to the release of insulin by exocytosis.
Glimepiride binds with a high rate of substitution to a beta-cell membrane protein bound to the ATP-dependent potassium channel, but the location of its binding site differs from the usual binding site for sulfonylureas.
Posapancreatic activity. Poppancreatic effects include, for example, improving the sensitivity of peripheral tissues to insulin and decreasing the utilization of insulin by the liver.
Type II diabetes mellitus in adults if blood sugar cannot be maintained by diet, exercise, and weight loss alone.
The drug is intended for the treatment of insulin-dependent type I diabetes mellitus, diabetic ketoacidosis, diabetic coma. The use of the drug is contraindicated in patients with severe renal or hepatic impairment. In case of severe impairment of kidney or liver function, the patient should be transferred to insulin.
The drug should not be taken by patients with hypersensitivity to glimepiride or to any auxiliary ingredient that is part of the drug, to sulfonylurea derivatives or other sulfonamide drugs (risk of developing hypersensitivity reactions).
The period of pregnancy and lactation (see section “Application during pregnancy or lactation”).